| 标题 |
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination |
| 网址 | |
| DOI | |
| 其它 |
期刊:Journal of Clinical Oncology 作者:Ana Arance; Luis de la Cruz‐Merino; Teresa M. Petrella; Rahima Jamal; Lars Ny; et al 出版日期:2022-07-22 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)